Verve Therapeutics Inc (VERV) - News Archive

In a strategic move signaling growth and confidence in its future endeavors, Verve Therapeutics, a Boston-based clinical-stage company focused on pioneering genetic medicines for cardiovascular disease, has announced th...

Innovative Advances in Gene Editing: Verve Therapeutics VERVE-102 in Hyperlipidemia Treatment Cardiovascular disease continues to be a leading cause of morbidity and mortality worldwide. As such, innovative treatment st...

Verve Therapeutics Expands Talent Pool with Strategic Inducement GrantsOn March 3, 2025, Verve Therapeutics, a Boston-based clinical-stage company dedicated to pioneering genetic medicines for cardiovascular diseases, m...

In a prominent move signaling growth and innovation, Verve Therapeutics, a Boston-based clinical-stage biotechnology company, has announced the granting of equity awards to new employees as part of its strategy to bolst...

Gene Editing’s Next Leap: Verve Therapeutics Charts New Territory with Promising Pipeline In the fast-evolving landscape of biotechnology, Verve Therapeutics is charting a bold course toward the future of precision medi...

In the rapidly evolving biotech sector, attracting top talent is essential for success, especially for companies like Verve Therapeutics. The Boston-based clinical-stage company, known for developing a novel class of ge...

In recent weeks, Verve Therapeutics, Inc. a biotechnology company at the forefront of gene editing technology, has found itself embroiled in a class action securities lawsuit that aims to recover damages for its investo...

In a significant development for shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV), two prominent law firms, The Rosen Law Firm and The Gross Law Firm, have issued crucial advisories regarding a securities class a...

Washington, D.C. - September 21, 2024 Investors who purchased securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022, and April 1, 2024, are being urged to take action ahead of an important deadlin...

Lead Plaintiff Deadline Approaches for Verve Therapeutics, Inc. Lawsuit: The Gross Law Firm Calls on Shareholders to Take Action by October 28, 2024 New York, September 10, 2024 The Gross Law Firm, a prominent securitie...

Verve Therapeutics Grants Equity Awards to New Employees as Part of 2024 Inducement Stock Incentive PlanIn a move to attract top talent and drive innovation in the field of genetic medicines for cardiovascular disease,...

BOSTON, Aug. 02, 2024 - Verve Therapeutics, a clinical-stage biotechnology company specializing in genetic medicines for cardiovascular disease, has recently announced the granting of equity awards to several new employ...

Verve Therapeutics, a leading biotechnology company focused on revolutionizing cardiovascular disease care through gene editing medicines, has once again announced the granting of equity awards to new employees as induc...

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Boston, May 31, 2024 - Verve Therapeutics, a clinical-stage biotechnology company revolutionizing cardiovascular disease care through si...

In a groundbreaking development, Verve Therapeutics has announced the dosing of its first patient in the Heart-2 Phase 1b clinical trial. This promising step involves the evaluation of VERVE-102, an investigational in v...

Boston-based biotechnology company, Verve Therapeutics, is making waves in the healthcare industry with its groundbreaking approach to cardiovascular disease treatment. The company has recently announced the granting of...

Verve Therapeutics Announces Exciting Progress in PCSK9 Program with Heart-1 Clinical Trial ResultsVerve Therapeutics, a leading biopharmaceutical company pioneering gene editing technologies for cardiovascular diseases...

Verve Therapeutics Grants Equity Awards to New Employees in Accordance with Nasdaq RulesBOSTON, March 28, 2024 - Verve Therapeutics, a clinical-stage biotechnology company specializing in gene editing medicines for card...

Gene Editing Company Verve Therapeutics Raises $143.8 Million in Public OfferingVerve Therapeutics, a clinical-stage biotechnology company specializing in the development of single-course gene editing medicines for card...

Verve Therapeutics Sets New Milestone in Cardiovascular Medicine with Successful Pricing of Public OfferingBOSTON, Nov. 28, 2023 - Verve Therapeutics, Inc. (Nasdaq: VERV) announces a significant achievement in the field...